246 related articles for article (PubMed ID: 33677674)
1. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
4. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
[TBL] [Abstract][Full Text] [Related]
6. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
7. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
[TBL] [Abstract][Full Text] [Related]
9. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
12. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Elliott MA; Wolf RC; Hook CC; Pruthi RK; Heit JA; Letendre LL; Tefferi A; Kaufmann SH; Mesa RA; Litzow MR
Leuk Lymphoma; 2004 Aug; 45(8):1545-9. PubMed ID: 15370205
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
Orvain C; Balsat M; Tavernier E; Marolleau JP; Pabst T; Chevallier P; de Gunzburg N; Cacheux V; Huguet F; Chantepie S; Caillot D; Chalandon Y; Frayfer J; Bonmati C; Lheritier V; Ifrah N; Dombret H; Boissel N; Hunault-Berger M
Blood; 2020 Jul; 136(3):328-338. PubMed ID: 32321172
[TBL] [Abstract][Full Text] [Related]
16. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.
Zuurbier SM; Lauw MN; Coutinho JM; Majoie CB; van der Holt B; Cornelissen JJ; Middeldorp S; Biemond BJ; Stam J
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1679-84. PubMed ID: 25934140
[TBL] [Abstract][Full Text] [Related]
18. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
19. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
.
Thu Huynh V; Bergeron S
Clin J Oncol Nurs; 2017 Oct; 21(5):E248-E259. PubMed ID: 28945721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
